1. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer
- Author
-
Xuefei Wang, Fulong Zhao, Yu Zs, Yakui Zhang, Hu Gd, and Xinghuo Zhang
- Subjects
CA15-3 ,Oncology ,Adult ,medicine.medical_specialty ,Bone Neoplasms ,Breast Neoplasms ,Real-Time Polymerase Chain Reaction ,Biochemistry ,Sensitivity and Specificity ,Breast cancer ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Aged ,DNA Primers ,Base Sequence ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Biochemistry (medical) ,Case-control study ,Cancer ,Bone metastasis ,Cell Biology ,General Medicine ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,MicroRNAs ,ROC Curve ,Case-Control Studies ,Biomarker (medicine) ,Female ,business ,Breast carcinoma - Abstract
OBJECTIVE: Bone metastasis is a major complication of advanced breast cancer. The present prospective case—control study investigated the involvement of microRNA (miR)-10b in the development of bone metastasis arising from primary breast carcinoma. METHODS: Serum miR-10b concentrations were determined by quantitative real-time reverse transcription—polymerase chain reaction in 122 patients with breast cancer, with or without bone metastases, and 59 age-matched healthy control subjects. RESULTS: Serum miR-10b concentrations were significantly higher in patients with bone metastases than in patients without bone metastases or control subjects. Serum miR-10b had an area under the receiver operating characteristic curve for the presence of bone metastases of 0.769, with 64.8% sensitivity and 69.5% specificity. CONCLUSION: These results suggest that serum miR-10b may be a useful biomarker for the identification of bone metastatic breast cancer.
- Published
- 2012